IKKγ NBD Inhibitory Peptide TFA
Based on 1 Customer Validation
IKKγ NBD Inhibitory Peptide TFA is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide TFA acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide TFA could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits.
For research use only. We do not sell to patients.
- Purity: 98.77%
- Formula: C172H260N49F3O44S1
- Molecular Weight:3807.32
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
In a canonical pathway, NF kappa B activation depends on the IKK complex activity, which is formed by three subunits (IKKκ and IKKβ and IKKγ/NEMO), thus the KKγ NBD Inhibitory Peptide TFA inhibits TNF-α-induced NF-kB activation[2].
IKKγ NBD Inhibitory Peptide TFA (10 μM; 90 min) prevents Doxorubicin (HY-15142A)-induced (15 μM; 4 h) p65 phosphorylation in BT-474 cells[2].
IKKγ NBD Inhibitory Peptide TFA (10 μM; 48 h) slightly inhibits BT-474 cell viability while it markedly enhances the effects on Doxorubicin[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Sprague-Dawley rats (255 g) with middle cerebral artery occlusion (MCAO)[3]
-
Dosage:40 μg/4 μL
-
Administration:Intracerebroventricular injection; 2 h before MCAO induction
-
Result:Significantly reduced striatal IL-1b level in IKK-NBD peptide treated rats.
Also resulted in reduced staining of microglial OX-42 and protection of BBB from ischemic insult.
Chemical Information
-
Appearance Solid
-
Molecular Weight 3807.32
-
Formula C172H260N49F3O44S1
-
Color White to off-white
-
Sequence Shortening
DRQIKIWFQNRRMKWKKTALDWSWLQTE
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 12.5 mg/mL (3.28 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhao J, et al. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 2018 Jun 11;16(6):e2004663. [Content Brief]
[2]. Tapia MA, et al. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle. 2007 Sep 15;6(18):2284-92. [Content Brief]
[3]. Desai A, et al. Neuroprotective potential of the NF-κB inhibitor peptide IKK-NBD in cerebral ischemia-reperfusion injury. Neurochem Int. 2010 Dec;57(8):876-83. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.2627 mL | 1.3133 mL | 2.6265 mL | 6.5663 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.